Commission consults on scrutinising drugs passing through EU to check counterfeiting
This article was originally published in SRA
Executive Summary
The European Commission is inviting stakeholder feedback on its plans to issue a delegated act concerning a new requirement of the Falsified Medicines Directive under which medicinal products being shipped through the EU for other destinations will have to face additional scrutiny by customs officials or other agencies to ensure they are not counterfeit1.